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Abstract 
This pilot study explores the metabolic changes associated with persistent post-
concussion syndrome (PCS) after mild traumatic brain injury (mTBI; >12 months post-
injury) using magnetic resonance spectroscopy (MRS). We hypothesised that those 
mTBI participants with PCS will have larger metabolic differences than those without. 
Data was collected from mTBI participants with PCS, mTBI participants without PCS 
and non-head injured participants (all groups: n=8). MRS metabolite profiles within the 
dorsolateral prefrontal cortex showed a reduced Creatine/Choline ratio in mTBI patients 
compared to control participants. This data provides initial evidence for residual 
metabolic changes in chronic mTBI patients, but there was no conclusive relationship 
between these metabolic changes and PCS symptom report. Creatine is involved in 
maintaining energy levels in cells with high or fluctuating energy demand, suggesting 
that there may be some residual energy impairment in chronic mTBI. 
 
Keywords: Magnetic Resonance Spectroscopy, mild Traumatic Brain Injury, persistent 
Post-Concussion Syndrome, Cognitive tasks, Creatine 
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Introduction 
Head injury induces a cascade of metabolic changes which result in a generalised 
cellular energy crisis, and can lead to cell death or disruption in neural connectivity 
[1,2]. It is thought that these mechanisms may underlie the symptoms (collectively 
known as post-concussion syndrome or PCS) observed after mild traumatic brain injury 
(mTBI), with significant metabolic alterations occurring even in the absence of these 
symptoms [1]. Magnetic resonance spectroscopy (MRS, [3]) can be used to measure 
metabolite concentrations in vivo and investigate whether subtle differences caused by 
this metabolic cascade are still evident in the long-term after injury. Creatine (Cr) is 
particularly suited for investigation of the energy metabolism after head injury. 
Impairment of the creatine/phospocreatine (Cr/PCr) system can lead to a deterioration in 
energy metabolism resulting in symptoms similar to those seen in PCS such as 
predisposition to migraines [4], mental retardation, and other neurological symptoms 
[5]. 
There have been variable observations of Creatine concentration in acute mTBI, with 
higher concentrations generally seen in white matter [6,7], and no difference [8] in gray 
matter or mixed areas. This is despite the more consistent detection of lower levels of 
N-Acetyl Aspartate (NAA [9]) and higher levels of Choline [7], and some initial 
evidence of reduction in glutamine and glutamate in gray matter [3,7].. There is a 
paucity of studies on creatine after head injury, and its concentration is conventionally 
thought to be stable in healthy individuals. However, reduced creatine concentration has 
been observed in clinical populations such as those with cancer [10] and stroke [11]. 
The present pilot study aims to investigate the long-term effect of mTBI (>1 year post-
injury) on metabolite concentrations in the dorsolateral prefrontal cortex (DLPFC, a 
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gray matter area involved in cognitive functions) in those reporting persistent PCS and 
those without on-going PCS. We conducted 3T 1H-MRS at short echo time, in 
conjunction with cognitive testing in 16 patients with mTBI (n=8 for those with/without 
PCS), and 8 non-head injured controls. Only a few studies [8,9,12] have considered 
mTBI participants beyond the acute stage, and none have examined the association of 
PCS and metabolite concentrations in the long term. We hypothesised that mTBI 
patients with persistent PCS would show greater metabolic changes (in particular in 
metabolites related to energy processing) than both mTBI patients without PCS and 
non-head injured controls. 
 
Methods 
Recruitment 
Participants were recruited from a database created by previous studies [13,14], with 
mTBI diagnosis according to ICD-10 criteria [15]. PCS diagnosis was based on 
Mittenberg and Strauman's modified DSM-IV criteria (which does not include cognitive 
testing) [16], and was achieved in the same way for control participants as mTBI 
participants (with the exception that controls had no “history of head trauma”). 
Inclusion criteria were that injury occurred at least one year previously, and exclusion 
criteria were report of litigation, major invasive head injury, chronic pain, or other 
neurological conditions. None of the participants had visible lesions using standard 
structural MRI. 24 participants were included in this study, divided into three groups 
containing 8 participants each: mTBI+PCS (participants who suffered an mTBI and 
have persistent PCS; mTBI-PCS (participants with mTBI but no PCS); Control 
(participants with no history of brain injury and no PCS). Group demographics and 
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questionnaire data are shown in Table 1. The study protocol was given a favourable 
opinion by the University of Surrey Ethics Committee, and informed consent was 
obtained from every participant. 
Questionnaires and Cognitive Testing 
The extent of PCS was measured through the Rivermead Post-Concussion symptoms 
Questionnaire (RPQ) and Rivermead Post-Concussion symptoms Questionnaire for 
Controls (RPQ-C; [17]). Other questionnaires assessed IQ (National Adult Reading 
Test, NART), everyday cognitive failures (Cognitive Failures Questionnaire, CFQ), 
daytime sleepiness (Epworth Sleepiness Scale, ESS), overall sleep quality (Pittsburgh 
Sleep Quality Index, PSQI), anxiety and depression (Hospital Anxiety and Depression 
Scale, HADS). In addition, working memory (n-Back: 0, 1, 2, 3-Back) and information 
processing speed (PVSAT [Paced Visual Serial Addition Task]: 1, 1.5, 2, 2.5 seconds) 
tasks were performed and error rates collected. 
MRS Procedure 
Single voxel MRS was performed over the right DLPFC (Fig. 1A) on a 3T Siemens’ 
Trio MR Scanner, using a PRESS sequence at short echo time (1.5x1.5x1.5cm; 
TE=30ms; TR=1500ms; CP coil, bandwidth=2000Hz; 2048 data points). Both water-
suppressed spectra (256 averages) and spectra without water suppression (16 averages) 
were acquired. Water unsuppressed spectra were used for eddy current correction and as 
an internal reference in order to measure metabolites relative to voxel water 
concentration. DLPFC was selected as the region of interest as it is differentially 
effected by mTBI, with differences observed using electrophysiological and fMRI 
studies  e.g. [18]. MRS was performed after sustained activation of DLPFC during the 
working memory and information processing speed tasks. The voxel was placed using 
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T1-weighted axial and coronal structural scans and anatomical landmarks, in the area of 
DLPFC as reported in an fMRI n-Back meta-analysis [19]. When placing the voxel, 
care was taken so that the voxel contained no CSF, and extra-voxel lipid saturation 
bands were used. Each spectrum was assessed to ensure good quality (e.g. poor water 
signal suppression, subject motion or insufficient magnetic field shimming) and absence 
of artefacts. The spectra obtained were processed using LC Model [20], using the 
default settings of water scaling, to obtain metabolite concentrations (total Creatine 
(Cr), total Choline (Cho), total NAA (NAA), Myoinositol (mIns) and 
Glutamate/Glutamine (GLX), all CRLB<15%), relative to water. Metabolite ratios were 
also calculated in order to reduce individual variability: NAA/Cho and Cr/Cho. 
Statistics 
A series of one-way ANOVAs, with post-hoc Bonferroni-corrected comparisons, were 
performed on the participant demographics and questionnaires The exception was 
gender, which was tested using chi-square. The cognitive tests were analysed using a 
mixed-model ANOVA with factor difficulty level (3-Back, 2-Back, 1-Back, 0-Back or 
1s, 1.5s, 2s, 2.5s) and between-subjects factor of group (Control, mTBI-PCS, 
mTBI+PCS). 
Metabolite concentrations were analysed using a univariate ANOVA with factor group 
(mTBI+PCS, mTBI-PCS, Control), and Bonferroni-adjusted post-hoc comparisons. 
Following on from this, univariate ANOVAs with factor mTBI (mTBI 
[mTBI+PCS/mTBI-PCS]; Control) and PCS (PCS; No PCS [mTBI-PCS/Control]) were 
carried out. Associations between metabolites, participant demographics and 
behavioural data were explored across groups (N=24) using Pearson’s correlations 
7 
 
 
 
where the data were normally distributed and Spearman’s Rho where the assumption of 
normality was violated. 
 
Results 
Questionnaires and Cognitive Testing 
Significant group differences (Table 1) were seen in post-concussion symptoms (RPQ; 
F(2, 21)=31.3, p<0.001), cognitive failures (CFQ; F(2, 21)=7.6, p<0.005), and sleep 
quality (PSQI; F(2, 21)=6.1, p<0.001). Comparisons revealed greater symptoms in the 
mTBI+PCS group compared to mTBI-PCS (RPQ: mean difference (m.d.)=13.5, 
p<0.001; PSQI: m.d.=4.1, p<0.01) or the Control group (RPQ: m.d.=21.4, p<0.001; 
CFQ: m.d.=27.6, p<0.005). No significant differences were observed for gender 
(p=0.5), age (p=0.2) or IQ (p=0.1). There was no significant correlation between IQ and 
any metabolite concentration, but both Creatine and Choline concentration tended to 
increase with increasing age across all participants (Cr: r(24)=0.6, p=0.005; Cho: 
r(24)=0.6, p=0.003) and in mTBI participants alone (Cr: r(16)=0.8, p=0.001; Cho: 
r(16)=0.6, p=0.03). 
----Insert Table 1 around here---- 
For the cognitive tests, there was a main effect of difficulty level (n-Back: F(3, 
52)=21.9, p<0.001; PVSAT: F(3, 41)=31.7, p<0.001), but no main effect of group (n-
Back: F(2, 20)=0.6, p=0.6; PVSAT: F(2, 21)=0.2, p=0.8) and no interaction between 
group and difficulty level.   
MRS Data 
A significant group difference Cr/Cho ratio was observed (Figure 1B, F(2, 21)=2.8, 
p=0.04), but no difference in total Creatine concentration (F(2, 21)=0.4, p=0.3). Further 
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analysis revealed that the participants with mTBI (mTBI+PCS/mTBI-PCS) had a 
smaller Cr/Cho ratio than the control participants (F(1, 22)=5.5, p=0.01), whereas there 
was only a trend for smaller Cr/Cho ratio in participants with PCS (mTBI+PCS) 
compared to those without PCS (F(1, 22)=2.3, p=0.07). Across participants, there was 
also a trend for greater PCS symptom report (RPQ) in those with lower Cr/Cho ratio 
(r(24)=-0.4, p=0.07). However, this was not seen in mTBI participants alone (r(16)=-
0.07, p=0.8). 
----Insert Fig. 1 around here---- 
There were no group differences for any other metabolites (NAA (F(2, 21)=0.6, p=0.6); 
NAA/Cho ratio (F(2, 21)=1.0, p=0.4); Cho (F(2, 21)=1.5, p=0.3); mIns (F(2, 21)=0.01, 
p=1); GLX (F(2, 21)=0.1, p=0.9)). However, higher error rate in the hardest PVSAT 
condition (1s) correlated with lower NAA/Cho ratio (r(24)=-0.5, p=0.03) and total 
Choline concentration (r(24)=0.5, p=0.02) across all participants. These correlations 
were not seen in mTBI participants alone (NAA/Cho ratio: r(16)= 0.3, p=0.2; Cho: 
r(16)=0.4, p=0.2).  
 
Discussion 
The present pilot study aimed to explore the metabolic alterations in chronic mTBI and 
their relationship to reported PCS symptoms. It provides initial evidence for residual 
metabolic changes, as participants with chronic mTBI exhibited lower Cr/Cho ratio 
compared to non-head injured controls (Fig. 1B). However, the trend for lower Cr/Cho 
in those with PCS, along with a trend for correlation between PCS symptom report 
(RPQ) and Cr/Cho ratio is not currently enough to substantiate an association between 
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these metabolite profiles and PCS diagnosis. Nevertheless, these results suggest an 
intriguing avenue for future research.  
Changes in brain metabolism in mTBI 
This study was particularly focused on alterations in metabolites used in energy 
metabolism, such as Creatine, in chronic mTBI. Creatine is involved in energy buffering 
and transport [5], impairment of its function leads to symptoms similar to those seen in 
PCS, and supplementation of Creatine can improve symptoms after injury [21,22].  
However, there was no difference in cognitive performance between groups in this 
study and no correlation between performance and Creatine.  
Furthermore, it was only the Cr/Cho ratio that was significantly different between 
groups, with no significant change in either absolute Creatine or absolute Choline 
concentration. Therefore, we cannot be certain whether the low Cr/Cho ratio is due to 
low Creatine concentration, a high Choline concentration, or a combination of both of 
these. Indeed, higher Choline has been seen in previous studies in acute mTBI [23], and 
could be indicative of neural inflammation or demyelination. 
The present study illustrates a metabolic difference between participants with mTBI and 
non head-injured controls, even a year after injury. However, it cannot definitively 
conclude that this difference is due to alterations in energy metabolism (reduced 
Creatine), and not inflammation or cell damage (increased Choline). 
Association with PCS 
The second aim of this experiment was to investigate whether lasting metabolite 
changes may be related to the severity of PCS symptoms. There was some suggestion 
that Cr/Cho ratio is reduced in those with PCS, and decreases in relation to greater RPQ 
symptom report. This offers some support for the hypothesis that those mTBI 
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participants with higher PCS symptoms will have greater metabolic alterations. 
However, the correlation was only a trend (p=0.07), and no correlation was observed 
when looking at mTBI participants alone (p=0.8). As such, the present study does not 
provide substantial enough evidence for our initial hypothesis.  
Association with Cognitive Performance 
Lower NAA/Cho ratio correlated with poorer cognitive performance in the hardest 
PVSAT condition. A similar association has been reported for the PASAT (an auditory 
version of the same task) in moderate to severe TBI [24]. However, there was also a 
significant correlation between higher total Choline concentration and poorer cognitive 
performance in the hardest PVSAT condition. The observed NAA/Cho ratio correlation 
could therefore be purely due to increased Choline in those with worse cognitive 
performance, or a combination lower NAA and higher Choline concentration. The 
association of increased Choline and cognitive performance is intriguing, especially in 
conjunction with the reduced Cr/Cho ratio in mTBI participants.  
Future Directions 
This pilot study provides tentative evidence of sustained changes in brain metabolism 
over a year after the episode of mild head injury. However, a larger scale follow-up 
experiment is required to examine our hypothesis more thoroughly and substantiate the 
more tentative findings. 
The variability inherent to mTBI may have masked subtle changes in both absolute 
Creatine or Choline concentration and cognitive performance. Participants taking part in 
this study had previously undertaken longer versions of the two cognitive tasks as part 
of a larger sample, with results showing that those with mTBI+PCS performed 
significantly worse on both tasks [14]. The lack of similar findings in this task could be 
11 
 
 
 
due to the smaller sample size, fewer trial repetitions in the shorter task used here, or the 
novel MRI environment. In this study, participants with mTBI+PCS reported higher 
subjective cognitive failures, PCS symptoms and sleep problems, suggesting that there 
are indeed some on-going behavioural problems. 
In addition, Creatine and Choline concentration increased with greater age, as seen in 
previous research [25]. This potentially limits the interpretation of the results, as another 
factor (age) is shown to systematically alter the metabolites of interest.  However, there 
is no significant effect of age between the groups, suggesting that the distributions of 
the ages within the groups are similar, despite numerically different group means.  
Indeed, if we add age as a covariate to the analysis there is still a significant reduction in 
Cr/Cho in mTBI participants compared to controls (F(2,21)=3.6, p=0.04), suggesting 
that it is unlikely to be causing the observed results. Future analyses will need to age-
match the groups in order to factor out this potential confound. Another potential 
limitation is that although corrections and modifications were made for CSF 
contamination, it was not possible to perform tissue segmentation to look at volume 
effects of gray and white matter. As metabolite concentrations differ between these two 
tissue types, this could confound the results.     
If a larger scale study was able to find equivocal evidence of a reduction in Creatine 
concentration in chronic mTBI, then it would suggest that dietary supplementation of 
Creatine may benefit those with chronic mTBI. Previous studies have observed that 
Creatine supplementation immediately after brain injury improved cognitive function, 
relieved headaches, dizziness and fatigue, reduced cell damage and post-traumatic 
amnesia and improved personality and communication [21,22]. However, Creatine has 
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only been administered in the acute phase of TBI, as soon as possible after the injury; it 
would be interesting to see if the effect is similar in participants with persistent PCS. 
Conclusion 
In conclusion, this is the first experiment to investigate metabolite changes in chronic 
mTBI at least a year after injury. Our data suggests that patients with mTBI do exhibit 
some on-going metabolic changes, with a reduction in Cr/Cho ratio. However, evidence 
for the association of this metabolic change with PCS symptom report was not 
substantial enough to warrant a definitive conclusion. A follow-up study with a larger 
sample is needed to confirm and expand upon the findings from this pilot work. 
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Table 1. Questionnaire and demographic data.  
 
Age 
Gende
r 
M/F 
TSI 
(yrs) 
NART RPQ CFQ 
HADS 
ESS PSQI Anxiet
y 
Depressio
n 
Control 
(n=8) 
22.5±1.
6 
4/4 - 
111.9±2.
2 
3.9±1.1 
25.6±4.
3 
5.9±1.3 1.8±1.2 
5.1±0.
6 
6.1±0.
6 
mTBI-
PCS (n=8) 
30.3±2.
9 
4/4 
3.9±1.
9 
117.6±1.
0 
11.8±2.
2 
35.4±4.
5 
3.9±1.0 1.8±0.8 
6.9±1.
4 
4.8±1.
0 
mTBI+PC
S (n=8) 
27.4±3.
8 
2/6 
5.5±2.
2 
112.0±2.
4 
25.3±2.
2 
53.3±6.
2 
7.8±1.2 4.5±1.1 
7.6±1.
7 
8.9±0.
9 
 
Results expressed as Mean±SEM. Questionnaire data is expressed as raw sum scores. Grey shading represents values 
significantly different from other groups. TSI: Time since Injury; NART: National Adult Reading Test; RPQ: Rivermead Post-
Concussion Questionnaire (scale 0-64); CFQ: Cognitive Failures Questionnaire (Scale 0-100); HADS: Hospital Anxiety and 
Depression Scale (scale 0-21); ESS: Epworth Sleepiness Scale (scale 0-24); PSQI: Pittsburgh Sleep Quality Index (scale 0-21). 
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Figure Legends 
Fig. 1 A: Example voxel placement at right dorsolateral prefrontal cortex (white square 
box) and MRS Spectra. Image on left is reversed so left side is right hemisphere. White 
area within box represents average BOLD response during n-Back task (All n-Back > 
Baseline) over all participants, masked for the right dorsolateral prefrontal cortex 
(p<0.05, FWE). B: Average metabolite concentration relative to water for each group. 
Cr: Creatine; tNAA: Total NAA (NAA and NAAG); tCho: Total Choline; mIns: 
Myoinositol; GLX: Glutamate and Glutamine. Cr/tCho and tNAA/tCho refer to the 
concentration of Creatine and NAA relative to Choline. Error Bars are Standard Error of 
the Mean (SEM). 
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